BioSpace News Archive

LIPAC Oncology LLC. today announced that management will participate in the following investor conferences, which will all be held virtually

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenting at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, held on September 22-25, 2021.

bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration

Pulmotect, Inc., a clinical-stage biotechnology company, announced positive topline results from the first of two Phase-2 clinical trials undertaken with the support of the US Department of Defense (DOD) to evaluate PUL-042 against COVID-19.

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, provided an update on the global regulatory approval process for the LungFit® PH system.

Cerevel Therapeutics announced today that Kathy Yi has resigned her position as chief financial officer to pursue other personal and professional interests.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET / 8:20 a.m. PT.

Immunis.AI, Inc. today announced it has presented key findings in a poster presentation at the International Conference on Clinical and Single Cell Analysis held in Lisbon, Portugal.

HUYABIO International announced today the first patient treated in a pivotal trial designed to measure the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb’s anti-PD-1, antibody Opdivo ®

- Roivant on track to close business combination with Montes Archimedes Acquisition Corp. and concurrent PIPE financing, and commence trading on Nasdaq on October 1 under the symbol